https://www.globenewswire.com/news-release/2025/03/26/3049523/0/en/Rezolute-Announces-Appointment-of-Rare-Disease-Commercial-Leader-Erik-Harris-to-its-Board-of-Directors.html
Rezolute Announces Appointment of Rare Disease Commercial
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing...
rare diseaseannouncesappointmentcommercial
https://markets.businessinsider.com/news/rzlt
Rezolute News | Markets Insider
Rezolute News: This is the News-site for the company Rezolute on Markets Insider
newsmarketsinsider
https://ir.rezolutebio.com/
Rezolute, Inc. (RZLT)
Rezolute is a clinical stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic...
inc
https://rezoluteconsulting.com/
Rezolute Consulting - Enterprise Cybersecurity Solutions
enterprise cybersecurityconsultingsolutions
https://www.fiercebiotech.com/biotech/after-posting-midphase-data-rezolute-banks-130m-take-treatment-rare-disease-pivotal-trial
Rezolute makes $130M to take disease drug into pivotal trial
May 2, 2022 - The biotech linked its candidate to a 75% reduction in severe low blood sugar events in children, emboldening it to raise $130 million to support a push into...
makestakediseasedrugpivotal
https://rezolute.com/
Rezolute – Websites that grow with you.
websitesgrow
https://www.benzinga.com/analyst-ratings/23/06/33046026/what-4-analyst-ratings-have-to-say-about-rezolute
What 4 Analyst Ratings Have To Say About Rezolute - Rezolute (NASDAQ:RZLT) - Benzinga
have to sayanalyst ratings
https://rezolutebio.com/
Rezolute | Hypoglycemia & Hyperinsulinism | Ersodetug
Jan 13, 2026 - Rezolute is a rare disease company focused on developing ersodetug, a potential treatment for hypoglycemia caused by congenital and tumor hyperinsulinism.
hypoglycemiahyperinsulinismersodetug